Bear market hits Europe’s innovator drug venture financing, losing pace with US
US-based biotech venture financing for innovator drugs reached a total of $72bn from 2017 to 2022, while Europe raised only…
By
US-based biotech venture financing for innovator drugs reached a total of $72bn from 2017 to 2022, while Europe raised only…
ByVenture capital firms seem to be more selective in their biotech investments following increased venture financing last year.
ByModerna’s positioning as US contractor for Covid-19 vaccines in a patent lawsuit marks a new development in the infringement disputes.
ByA recent study has shed light on the size of markups imposed by hospitals for parenteral cancer drugs in the…
ByWorld Health Day 2022 offers investors the opportunity to think beyond the laboratories and consider the impact their healthcare activities…
ByWestern sanctions may make companies cautious about entering any strategic alliances with or receiving any capital from Russia.
ByOverall venture capital financing from US investors for foreign innovator drugs is almost 500 times that from Russian investors.
ByIt remains to be seen whether the special purpose acquisition company (SPAC) trend will continue as markets rebuild post-pandemic.
ByThank you for subscribing to Pharmaceutical Technology